Pharma BD Deal Intelligence
Sanofi's $100M-upfront, up-to-$5.2B AI-discovery bet on Exscientia survived its partner's own near-death: Exscientia was acquired by Recursion Pharmaceuticals in November 2024, delisting its ADSs, yet the up-to-15-candidate collaboration continued under Recursion into 2025.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi is paying $100 million upfront for an artificial intelligence-driven drug discovery deal with Exscientia that could be worth up to $5.3 billion, the…
Sanofi and U.K.-based Exscientia are extending their AI-drug-discovery partnership in a deal worth up to $5.3 billion to develop as many as 15 small-molecule…
Exscientia is restructuring and cutting roughly a quarter of its workforce as it prioritizes its highest-conviction wholly-owned oncology programs and slows…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Sanofi and Exscientia announced a strategic research collaboration and license agreement on January 7, 2022 to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia's end-to-end AI-driven platform using actual patient samples. Exscientia received $100M upfront, with up to ~$5.2B in additional milestones plus tiered royalties. Since then the relationship has materially evolved: Exscientia plc was acquired by Recursion Pharmaceuticals (Nasdaq: RXRX) in an all-stock business combination completed November 20, 2024 (Exscientia became a wholly owned subsidiary and its EXAI ADSs were delisted from Nasdaq), so the Sanofi collaboration is now executed by Recursion. The partnership was not terminated and continues to advance: as of Q2 2025, Recursion reported a multi-target collaboration for up to 15 best-in-class or first-in-class programs across oncology and immunology with $130 million in upfront and milestone payments achieved to date (including a $7M immunology milestone in 2Q 2025), with each program carrying potential for over $300 million in additional milestone payments.
1.9M US cases/yr · $300.0B Combined global oncology + immunology market (2022)
Oncology and immunology represent the two largest therapeutic areas by global pharmaceutical revenue, collectively accounting for more than $300B in 2022 sales. The U.S. cancer burden alone exceeds 1.9M new diagnoses and 600,000 deaths annually per the American Cancer Society, while autoimmune and inflammatory diseases (rheumatoid arthritis, IBD, psoriasis, atopic dermatitis, lupus, multiple sclerosis) collectively affect 24-50M Americans depending on definition. The Sanofi-Exscientia collaboration sits at the discovery stage and is structured to identify up to 15 small-molecule candidates across both areas using Exscientia's AI-driven precision medicine platform — which combines machine-learning target identification with patient-derived primary cell phenotypic screening. The strategic logic is to compress hit-to-lead and lead-optimization timelines by 50-70% versus traditional medicinal chemistry, while improving clinical translation by selecting molecules that show activity in actual patient tissue rather than immortalized cell lines or rodent models. Commercial impact is multi-decade and entirely back-loaded — the deal is preclinical with no commercial assets and depends on conversion of AI-identified targets into IND-enabled candidates.
The AI-driven drug discovery competitive landscape consolidated rapidly in 2021-2023 as large pharma signed multi-billion-dollar discovery pacts with computationally enabled biotechs. Comparable platform deals include Sanofi-Atomwise (target ID), BMS-Exscientia (2019, oncology), Bayer-Recursion ($1.5B, fibrosis/oncology), Genentech-Recursion ($1B+ neuroscience), AstraZeneca-BenevolentAI (multi-target), Lilly-Verge Genomics, Pfizer-CytoReason (immunology), and Boehringer-Cyclica. The Exscientia platform differentiator is patient-tissue phenotypic validation rather than purely in-silico target prediction, which positions it against Recursion's image-based phenotypic screening and Insitro's ML-on-cellular-data approach. On the oncology and immunology output side, eventual molecules from the deal will compete in mature MOA classes — likely small-molecule kinase inhibitors, E3-ligase recruiters/PROTACs, and oral chemotype precision-medicine drugs — against established franchises from Roche/Genentech, Merck, AstraZeneca, AbbVie and Bristol Myers Squibb. The deal extends Sanofi's earlier 2017 Exscientia bispecific small-molecule pact and signals continued conviction in AI discovery despite mixed industry-wide clinical readouts through 2024.
Recursion Pharmaceuticals (Nasdaq: RXRX) completed its all-stock acquisition of Exscientia plc on November 20, 2024. Exscientia became a wholly owned subsidiary of Recursion and its EXAI ADSs were delisted from Nasdaq; the Sanofi AI-discovery collaboration transferred to Recursion.
As of Q2 2025, Recursion reported the Sanofi collaboration (assumed from Exscientia) continues for up to 15 oncology/immunology programs with $130 million in upfront and milestone payments achieved to date, including a $7 million immunology milestone in 2Q 2025; each program carries >$300M additional milestone potential.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Exscientia plc (this deal) | 2022 | $5.3B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2022 deals · Sanofi SA deals · Immunology deals